PBAC's latest decision on Degarelix: Recommended with restriction (2017). Considered for Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2010
Submissions
2
2010 → 2017
Eligible population
Adults with locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
leuprorelin
Economic model
Cost-minimisation
ICER note
This was a minor submission requesting a change in restriction level only. Cost-minimisation basis was established at the original July 2010 listing; no new economic evaluation was conducted.
Submission history
Jul 2010: Recommended with restriction · Authority Required
Mar 2017: Recommended with restriction · Restricted